Jonathan Aschoff
Stock Analyst at Roth Capital
(0.49)
# 4,196
Out of 5,149 analysts
39
Total ratings
24.49%
Success rate
-35.01%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Buy | $57 → $55 | $24.19 | +127.37% | 2 | Feb 26, 2026 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.47 | +2,240.92% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.91 | +135.69% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $199,800 → $106,560 | $6.66 | +1,599,900.00% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $0.21 | +8,541.38% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $1.43 | +49,830.07% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $500 | $1.59 | +31,346.54% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $2.27 | +43,952.86% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $2.68 | +31,243.28% | 4 | Mar 28, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $1.98 | +908,990.91% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $11.42 | +162.70% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $5.03 | +3,876.14% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $8.15 | +71.78% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28,800 → $86,400 | $1.23 | +7,024,290.24% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.86 | +330.11% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.78 | +5,517.98% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.89 | +44,602.73% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $5.91 | +542.98% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.68 | +5,614.29% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.40 | +828.57% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $57 → $55
Current: $24.19
Upside: +127.37%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.47
Upside: +2,240.92%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.91
Upside: +135.69%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $199,800 → $106,560
Current: $6.66
Upside: +1,599,900.00%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $0.21
Upside: +8,541.38%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $1.43
Upside: +49,830.07%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $500
Current: $1.59
Upside: +31,346.54%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $2.27
Upside: +43,952.86%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $2.68
Upside: +31,243.28%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $1.98
Upside: +908,990.91%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $11.42
Upside: +162.70%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $5.03
Upside: +3,876.14%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $8.15
Upside: +71.78%
Feb 14, 2023
Maintains: Buy
Price Target: $28,800 → $86,400
Current: $1.23
Upside: +7,024,290.24%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.86
Upside: +330.11%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $1.78
Upside: +5,517.98%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.89
Upside: +44,602.73%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $5.91
Upside: +542.98%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.68
Upside: +5,614.29%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.40
Upside: +828.57%